Contractions in human coronary bypass vessels stimulated by extracellular nucleotides.

[1]  Darrell R. Abernethy,et al.  International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.

[2]  D. Erlinge,et al.  P2 Receptor Expression Profiles in Human Vascular Smooth Muscle and Endothelial Cells , 2002, Journal of cardiovascular pharmacology.

[3]  C. Kuhn,et al.  UDP acts as a growth factor for vascular smooth muscle cells by activation of P2Y(6) receptors. , 2002, American journal of physiology. Heart and circulatory physiology.

[4]  S. Yusuf,et al.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. , 2001, The New England journal of medicine.

[5]  T. K. Harden,et al.  Differential Regulation of the Uridine Nucleotide-activated P2Y4 and P2Y6 Receptors , 2001, The Journal of Biological Chemistry.

[6]  B S Khakh,et al.  International union of pharmacology. XXIV. Current status of the nomenclature and properties of P2X receptors and their subunits. , 2001, Pharmacological reviews.

[7]  T. K. Harden,et al.  The stable pyrimidines UDPβS and UTPγS discriminate between the P2 receptors that mediate vascular contraction and relaxation of the rat mesenteric artery , 2000 .

[8]  T. K. Harden,et al.  Characterization of contractile P2 receptors in human coronary arteries by use of the stable pyrimidines uridine 5'-O-thiodiphosphate and uridine 5'-O-3-thiotriphosphate. , 2000, The Journal of pharmacology and experimental therapeutics.

[9]  D. Steinbrüchel.  Arterial Revascularization: Evidence or Presumption?: A Critical Review , 2000 .

[10]  F. Rosenfeldt,et al.  Pharmacology of coronary artery bypass grafts. , 1999, The Annals of thoracic surgery.

[11]  R. Poelmann,et al.  Smooth muscle cells and fibroblasts of the coronary arteries derive from epithelial-mesenchymal transformation of the epicardium , 1999, Anatomy and Embryology.

[12]  D. Erlinge,et al.  Endothelial P2Y receptors induce hyperpolarisation of vascular smooth muscle by release of endothelium-derived hyperpolarising factor. , 1999, European journal of pharmacology.

[13]  G Burnstock,et al.  Receptors for purines and pyrimidines. , 1998, Pharmacological reviews.

[14]  E. Barnard,et al.  Phenotype changes of the vascular smooth muscle cell regulate P2 receptor expression as measured by quantitative RT-PCR. , 1998, Biochemical and biophysical research communications.

[15]  P. Pacaud,et al.  P2X7 receptor activation-induced contraction and lysis in human saphenous vein smooth muscle. , 1998, Circulation research.

[16]  D. Erlinge.  Extracellular ATP: a growth factor for vascular smooth muscle cells. , 1998, General pharmacology.

[17]  D. Erlinge,et al.  P2U‐receptor mediated endothelium‐dependent but nitric oxide‐independent vascular relaxation , 1998, British journal of pharmacology.

[18]  W. Watt,et al.  Enzymatic synthesis of UTPγS, a potent hydrolysis resistant agonist of P2U‐purinoceptors , 1996 .

[19]  D. Clement.  A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996 .

[20]  G. Burnstock.  Dual Control of Local Blood Flow by Purines a , 1990, Annals of the New York Academy of Sciences.

[21]  J. L. Gordon.  Extracellular ATP: effects, sources and fate. , 1986, The Biochemical journal.

[22]  G. Burnstock,et al.  The use of the slowly degradable analog, alpha, beta-methylene ATP, to produce desensitisation of the P2-purinoceptor: effect on non-adrenergic, non-cholinergic responses of the guinea-pig urinary bladder. , 1982, European journal of pharmacology.